https://orcid.org/0000-0002-2358-4278
Abstract
Inflammatory form of Waldenström macroglobulinemia (iWM) predicts outcomes after immuno-chemotherapy and Bruton tyrosine kinase inhibitors, but its origin is unknown. Here, we unravel increased clonal hematopoiesis in patients with iWM (61% vs 23% in noninflammatory WM), suggesting a contribution of environmental cells to iWM.
References
1.
Quintanilla-Martinez
L
. The 2016 updated WHO classification of lymphoid neoplasias
. Hematol Oncol
. 2017
;35
(suppl 1
):37
-45
.2.
Treon
SP
, Xu
L
, Yang
G
, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia
. N Engl J Med
. 2012
;367
(9
):826
-833
.3.
Hunter
ZR
, Xu
L
, Yang
G
, et al. The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
. Blood
. 2014
;123
(11
):1637
-1646
.4.
Nguyen-Khac
F
, Lambert
J
, Chapiro
E
, et al. Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström’s macroglobulinemia
. Haematologica
. 2013
;98
(4
):649
-654
.5.
Castillo
JJ
, Advani
RH
, Branagan
AR
, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström macroglobulinaemia
. Lancet Haematol
. 2020
;7
(11
):e827
-e837
.6.
Elessa
D
, Debureaux
P
, Villesuzanne
C
, et al. Inflammatory Waldenström’s macroglobulinaemia: a French monocentric retrospective study of 67 patients
. Br J Haematol
. 2022
;197
(6
):728
-735
.7.
Forgeard
N
, Baron
M
, Caron
J
, et al. Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation
. Haematologica
. 2022
;107
(11
):2720
-2724
.8.
Debureaux
P-E
, Forgeard
N
, Elessa
D
, et al. Inflammation is predictive of outcome in Waldenström macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life study
. Haematologica
. 2024
;109
(1
):325
-330
.9.
Kaushal
A
, Nooka
AK
, Carr
AR
, et al. Aberrant extrafollicular B cells, immune dysfunction, myeloid inflammation, and MyD88-mutant progenitors precede Waldenstrom macroglobulinemia
. Blood Cancer Discov
. 2021
;2
(6
):600
-615
.10.
Jiang
J
, Yang
G
, Liu
X
, et al. Microarray analysis of the peripheral monocytes from Waldenstrom’s macroglobulinemia patients reveals a distinct gene expression profile [abstract]
. Blood
. 2010
;116
(21
):281
.11.
García-Sanz
R
, Dogliotti
I
, Zaccaria
GM
, et al. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival
. Br J Haematol
. 2021
;192
(5
):843
-852
.12.
Danesin
N
, Lo Schirico
M
, Scapinello
G
, et al. Waldenström Macroglobulinemia in very elderly (≥75-year-old) patients: a 33-year-retrospective cohort study in an Italian University Hospital
. Hemasphere
. 2023
;7
(10
):e964
.13.
Jaiswal
S
, Fontanillas
P
, Flannick
J
, et al. Age-related clonal hematopoiesis associated with adverse outcomes
. N Engl J Med
. 2014
;371
(26
):2488
-2498
.14.
Bick
AG
, Weinstock
JS
, Nandakumar
SK
, et al. Inherited causes of clonal haematopoiesis in 97,691 whole genomes
. Nature
. 2020
;586
(7831
):763
-768
.15.
Jaiswal
S
, Natarajan
P
, Silver
AJ
, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease
. N Engl J Med
. 2017
;377
(2
):111
-121
.16.
Tahri
S
, Mouhieddine
TH
, Redd
R
, et al. Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia
. Blood Adv
. 2022
;6
(7
):2230
-2235
.17.
Poulain
S
, Roumier
C
, Bertrand
E
, et al. TP53 mutation and its prognostic significance in Waldenstrom’s macroglobulinemia
. Clin Cancer Res
. 2017
;23
(20
):6325
-6335
.18.
Sébert
M
, Passet
M
, Raimbault
A
, et al. Germline DDX41 mutations define a significant entity within adult MDS/AML patients
. Blood
. 2019
;134
(17
):1441
-1444
.19.
Guerrera
ML
, Tsakmaklis
N
, Xu
L
, et al. MYD88 mutated and wild-type Waldenström’s macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4
. Haematologica
. 2018
;103
(9
):e408
-e411
.20.
Wenzl
K
, Manske
MK
, Sarangi
V
, et al. Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma
. Blood Cancer J
. 2018
;8
(10
):97
. 11.21.
Zhao
L-P
, Boy
M
, Azoulay
C
, et al. Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease
. Leukemia
. 2021
;35
(9
):2720
-2724
.22.
Pathak
S
, Rowczenio
DM
, Owen
RG
, et al. Exploratory study of MYD88 L265P, rare NLRP3 variants, and clonal hematopoiesis prevalence in patients with Schnitzler syndrome
. Arthritis Rheumatol
. 2019
;71
(12
):2121
-2125
.23.
Guermouche
H
, Ravalet
N
, Gallay
N
, et al. High prevalence of clonal hematopoiesis in the blood and bone marrow of healthy volunteers
. Blood Adv
. 2020
;4
(15
):3550
-3557
.24.
Mondello
P
, Paludo
J
, Novak
JP
, et al. Molecular clusters and tumor-immune drivers of IgM monoclonal gammopathies
. Clin Cancer Res
. 2023
;29
(5
):957
-970
.25.
Richardson
K
, Castillo
JJ
, Sarosiek
SR
, et al. Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemia
. Blood Adv
. 2024
;8
(9
):2133
-2137
.© 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2025
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal